



**Commercial/Healthcare Exchange Quantity Limit Criteria**  
*Effective: May 8<sup>th</sup>, 2019*

**Quantity Limit Name:** Inbrija

**Products Affected:** Inbrija (levodopa inhalation powder) capsules for inhalation

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

Coverage will be provided only up to the limits specified below:  
Inbrija: 300 capsules per 30 days

**References:**

1. Inbrija™ powder for inhalation [prescribing information]. Ardsley, NY: Acorda Therapeutics, Inc.; December 2018

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	4/23/2019

Last Res. April 23, 2019



Confidential Information

This document is confidential and proprietary to Emblemhealth. Unauthorized use and distribution are prohibited.